Written question WQ89612
- Asked by
- Andrew RT DaviesConservative
- To be answered by
- Minister for Health and Social Services
- Tabled
- Due
- Answered
- Time to answer
- 7 days
Question
What consideration has the Minister given to Ruxolitinib being available for the treatment of myelofibrosis for those aged under 65?
Answer
Answered by Minister for Health and Social Services
In March 2016, NICE published guidance recommending Ruxolitinib (Jakavi) as a possible treatment for treating disease-related splenomegaly or symptoms in adults with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis, only, if they have intermediate‑2 or high-risk disease.
In line with directions to the NHS in Wales, health boards should make Ruxolitinib available where clinically appropriate in accordance with NICE’s guidance.